scholarly journals Advances of intravenous immunoglobulin G in modulation of anti-fetal immunity in selected at-risk populations: science and therapeutics

2014 ◽  
Vol 178 ◽  
pp. 120-122 ◽  
Author(s):  
O. B. Christiansen
Keyword(s):  
At Risk ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Intravenous Immunoglobulin G ◽  
At Risk Populations

A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome

1990 ◽  
Vol 89 (5) ◽  
pp. 554-560 ◽  
Author(s):  
Phillip K. Peterson ◽  
Judy Shepard ◽  
Mark Macres ◽  
Carlos Schenck ◽  
John Crosson ◽  
...  
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Controlled Trial ◽  
Chronic Fatigue ◽  
Fatigue Syndrome ◽  
Intravenous Immunoglobulin G

scholarly journals Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0139828 ◽  
Author(s):  
Willem Jan R. Fokkink ◽  
David Falck ◽  
Tom C. M. Santbergen ◽  
Ruth Huizinga ◽  
Manfred Wuhrer ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Pharmaceutical Products ◽  
Intravenous Immunoglobulin G

The Genetics of Obsessive-Compulsive Disorder: An Immunologic Perspective

CNS Spectrums ◽  
1999 ◽  
Vol 4 (6) ◽  
pp. 71-77 ◽  
Author(s):  
Mark Hyman Rapaport ◽  
Cathy G. McAllister
Keyword(s):  
Cell Wall ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Human Tissue ◽  
Clinical Studies ◽  
Obsessive Compulsive ◽  
Hemolytic Streptococcus ◽  
Compulsive Disorder ◽  
M Proteins ◽  
Intravenous Immunoglobulin G

ABSTRACTThis article presents a rationale for the hypothesis that an autoimmune mechanism might be involved in the pathogenesis of some forms of obsessive-compulsive aborder (OCO). Existing clinical studies suggesting that some individuals with OCD may have an autoimmune-mediated disorder are briefly summarized. A case example where intravenous immunoglobulin G has been successfully used to treat an adult with OCD spectrum disorder is presented. Preclinical data demonstrating that fragments from the group Αβ hemolytic streptococcus cell wall M proteins can generate antibodies that bind to rat and human tissue are also presented.

scholarly journals Cardiac rhythm abnormalities during intravenous immunoglobulin G(IVIG) infusion in two newborn infants: coincidence or association?

2015 ◽  
Vol 3 (9) ◽  
pp. 731-734 ◽  
Author(s):  
Sinan Tufekci ◽  
Asuman Coban ◽  
Meltem Bor ◽  
Beril Yasa ◽  
Kemal Nisli ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Cardiac Rhythm ◽  
Newborn Infants ◽  
Ivig Infusion ◽  
Intravenous Immunoglobulin G

Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbα antibodies

Blood ◽  
2006 ◽  
Vol 108 (3) ◽  
pp. 943-946 ◽  
Author(s):  
Michelle Lee Webster ◽  
Ebrahim Sayeh ◽  
Min Crow ◽  
Pingguo Chen ◽  
Bernhard Nieswandt ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Intravenous Immunoglobulin ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Immunoglobulin G ◽  
Ivig Treatment ◽  
Relative Efficacy ◽  
Thrombocytopenic Purpura ◽  
Antiplatelet Antibodies ◽  
Intravenous Immunoglobulin G

Abstract Intravenous immunoglobulin G (IVIG) is used to treat idiopathic thrombocytopenic purpura (ITP). Although many patients benefit from IVIG, some are refractory to this therapy. ITP is characterized by platelet clearance mediated primarily by antiplatelet antibodies against GPIIbIIIa and/or the GPIbα complex. These 2 groups of antibodies may induce ITP through different mechanisms. We tested the hypothesis that IVIG may not be equally effective in preventing ITP caused by anti-GPIIbIIIa versus anti-GPIbα antibodies in mice. Thrombocytopenia was induced in BALB/c mice using monoclonal antibodies against either mouse GPIIbIIIa (JON1, JON2, and JON3) or GPIbα (p0p3, p0p4, p0p5, p0p9, and p0p11). Pretreatment with IVIG significantly ameliorated ITP in all anti-GPIIbIIIa–injected animals. Conversely, IVIG failed to prevent ITP in all anti-GPIbα–treated mice, except for p0p4. These results were repeated in C57BL/6 mice, and with different IVIG preparations. These data in mice suggest that patients with ITP mediated by anti-GPIbα antibodies may be less responsive to IVIG treatment.

Sign in / Sign up

Export Citation Format

Share Document